{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:27:26Z","timestamp":1786116446025,"version":"build-2736575974"},"reference-count":141,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374395, 82405084"],"award-info":[{"award-number":["82374395, 82405084"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008990","name":"Science and Technology Department of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012175","name":"Zhejiang Traditional Chinese Medicine Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Patients with systemic lupus erythematosus (SLE) are at markedly increased risk of premature atherosclerosis (AS) and atherosclerotic cardiovascular disease (ASCVD), and this excess risk is not fully explained by traditional Framingham factors. Increasing evidence suggests that SLE does not merely coexist with AS; rather, persistent immune activation and immunometabolic dysregulation reshape the vascular microenvironment toward endothelial dysfunction, lipoprotein impairment, maladaptive myeloid activation, and immunothrombosis. This review synthesizes current epidemiologic, mechanistic, and translational evidence supporting an immune\u2013metabolic\u2013vascular framework for SLE-accelerated AS. We focus on four interconnected processes: (1) type I interferon (IFN-I)-associated endothelial injury and defective vascular repair; (2) neutrophil extracellular traps (NETs) and oxidative modification of high-density lipoprotein, contributing to dysfunctional or pro-inflammatory HDL; (3) monocyte\/macrophage immunometabolic reprogramming, which favors foam-cell formation and inflammasome activation; and (4) T- and B-cell metabolic disequilibrium, which sustains vascular inflammation and autoantibody-driven immune injury. Across these pathways, metabolic rewiring appears to function not merely as a parallel phenomenon, but as a shared amplifier linking systemic autoimmunity to lesion-level vascular progression. Recognizing these shared checkpoints has therapeutic implications. These observations suggest that future strategies may need to integrate upstream metabolic resetting, midstream immune-specific blockade, and downstream lipid or vascular-wall protection, rather than relying solely on lipid lowering or broad immunosuppression. However, most available evidence remains confined to mechanistic studies, biomarker readouts, or surrogate vascular endpoints, and dedicated trials with plaque or cardiovascular event outcomes are still needed.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1841513","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:20:54Z","timestamp":1781068854000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic lupus erythematosus\u2013driven accelerated atherosclerosis: the immune\u2013metabolic\u2013vascular axis and therapeutic implications"],"prefix":"10.3389","volume":"17","author":[{"given":"Meiwei","family":"Jiang","sequence":"first","affiliation":[{"name":"The Second School of Clinical Medicine, Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FengQi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MinZhe","family":"Ren","sequence":"additional","affiliation":[{"name":"The Second School of Clinical Medicine, Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiYu","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiJun","family":"Xie","sequence":"additional","affiliation":[{"name":"College of Basic Medical Science, Zhejiang Chinese Medical University","place":["Hangzhou, China"]},{"name":"Jinhua Research Institute, Zhejiang Chinese Medical University","place":["Jinhua, China"]},{"name":"The Affiliated Lishui Hospital of Traditional Chinese Medicine, Zhejiang Chinese Medical University","place":["Lishui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[{"name":"The Second School of Clinical Medicine, Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/00006254-197704000-00018","article-title":"Menopause and risk of cardiovascular disease: the Framingham study","volume":"85","author":"Kannel","year":"1976","journal-title":"Ann Intern Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009122","article-title":"Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study","volume":"145","author":"Manzi","year":"1997","journal-title":"Am J Epidemiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheumatic Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.07.021","article-title":"Estrogen in cardiovascular disease during systemic lupus erythematosus","volume":"36","author":"Gilbert","year":"2014","journal-title":"Clin Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.906475","article-title":"Sex hormones affect the pathogenesis and clinical characteristics of systemic lupus erythematosus","volume":"9","author":"Kim","year":"2022","journal-title":"Front Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2012.00165","article-title":"Vascular aging in women: is estrogen the fountain of youth","volume":"3","author":"Novella","year":"2012","journal-title":"Front Physiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.104.507996","article-title":"Accelerated atherosclerosis in autoimmune rheumatic diseases","volume":"112","author":"Shoenfeld","year":"2005","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/oxfimm\/iqad005","article-title":"A cellular overview of immunometabolism in systemic lupus erythematosus","volume":"4","author":"Psarras","year":"2023","journal-title":"Oxford Open Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0833","article-title":"The link between dysregulated immunometabolism and vascular damage: implications for the development of atherosclerosis in systemic lupus erythematosus and other rheumatic diseases","volume":"51","author":"Yennemadi","year":"2024","journal-title":"J Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.849086","article-title":"Endothelial dysfunction in systemic lupus erythematosus and systemic sclerosis: a common trigger for different microvascular diseases","volume":"9","author":"Moschetti","year":"2022","journal-title":"Front Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel paradigms in systemic lupus erythematosus","volume":"393","author":"D\u00f6rner","year":"2019","journal-title":"Lancet (London England)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.11.013","article-title":"Contributions of B cells to lupus pathogenesis","volume":"62","author":"Sang","year":"2014","journal-title":"Mol Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00772","article-title":"Innate immune cells' contribution to systemic lupus erythematosus","volume":"10","author":"Herrada","year":"2019","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1536020","article-title":"Immunometabolism of Tregs: mechanisms, adaptability, and therapeutic implications in diseases","volume":"16","author":"Lu","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s534574","article-title":"The pathophysiological role of mitochondrial oxidative stress in rheumatic diseases","volume":"18","author":"Ma","year":"2025","journal-title":"J Inflammation Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/bor.0000000000000738","article-title":"Immunometabolism in the pathogenesis of systemic lupus erythematosus: an update","volume":"32","author":"Romo-Tena","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1155421","article-title":"B cell activation via immunometabolism in systemic lupus erythematosus","volume":"14","author":"Iwata","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76478","article-title":"Cutaneous manifestations of systemic lupus erythematosus and their correlation with cardiac involvement","volume":"16","author":"Zeb","year":"2024","journal-title":"Cureus"},{"key":"B20","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1093\/hmg\/ddaf066","article-title":"Recent insights into the role of innate immunity in lupus","volume":"34","author":"Robinson","year":"2025","journal-title":"Hum Mol Genet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1708616","article-title":"Multi-omics approach to dissect the significance of lipid metabolism in helper T cell subset","volume":"16","author":"Kanno","year":"2025","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1371708","article-title":"A global view of T cell metabolism in systemic lupus erythematosus","volume":"15","author":"Goetz","year":"2024","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.20900\/immunometab20200017","article-title":"Metabolic fitness of T cells in autoimmune disease","volume":"2","author":"Wu","year":"2020","journal-title":"Immunometabolism"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.20900\/immunometab20200009","article-title":"T cell metabolism in lupus","volume":"2","author":"Vukelic","year":"2020","journal-title":"Immunometabolism"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.04.006","article-title":"Metabolism as a key regulator in the pathogenesis of systemic lupus erythematosus","volume":"48","author":"Takeshima","year":"2019","journal-title":"Semin Arthritis Rheumatism"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/art.34502","article-title":"N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Lai","year":"2012","journal-title":"Arthritis Rheumatism"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet (London England)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4049\/jimmunol.1501537","article-title":"Glucose oxidation is critical for CD4+ T cell activation in a mouse model of systemic lupus erythematosus","volume":"196","author":"Yin","year":"2016","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"274ra18","DOI":"10.1126\/scitranslmed.aaa0835","article-title":"Normalization of CD4+ T cell metabolism reverses lupus","volume":"7","author":"Yin","year":"2015","journal-title":"Sci Transl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00797-8","article-title":"Vascular damage in systemic lupus erythematosus","volume":"20","author":"Ambler","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110200","article-title":"New and emerging therapies for systemic lupus erythematosus","volume":"263","author":"Papachristodoulou","year":"2024","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1101\/2025.01.28.25321013","article-title":"Mitochondrial Dysfunction Drives Natural Killer Cell Dysfunction in Systemic Lupus Erythematosus","volume-title":"medRxiv: the preprint server for health sciences","author":"Fluder","year":"2025"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Sci (New York NY)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1385\/1-59259-305-4:039","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4027","article-title":"Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease","volume":"22","author":"Lood","year":"2016","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-019-0151-1","article-title":"DNA sensing by the cGAS-STING pathway in health and disease","volume":"20","author":"Motwani","year":"2019","journal-title":"Nat Rev Genet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215006109","article-title":"STING manifests self DNA-dependent inflammatory disease","volume":"109","author":"Ahn","year":"2012","journal-title":"PNAS"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43743-9","article-title":"TET2-mediated tumor cGAS triggers endothelial STING activation to regulate vasculature remodeling and anti-tumor immunity in liver cancer","volume":"15","author":"Lv","year":"2024","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1420217112","article-title":"Suppression of systemic autoimmunity by the innate immune adaptor STING","volume":"112","author":"Sharma","year":"2015","journal-title":"PNAS"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i","article-title":"Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus","volume":"44","author":"Esdaile","year":"2001","journal-title":"Arthritis Rheumatism"},{"key":"B41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/art.41059","article-title":"High-density lipoprotein in lupus: disease biomarkers and potential therapeutic strategy","volume":"72","author":"Kim","year":"2020","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/art.24677","article-title":"Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus","volume":"60","author":"McMahon","year":"2009","journal-title":"Arthritis Rheumatism"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejr.2013.07.003","article-title":"Anti-apolipoprotein A-I antibodies and paraoxonase 1 activity in systemic lupus erythematosus","volume":"12","author":"Ahmed","year":"2013","journal-title":"EXCLI J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1196\/annals.1422.009","article-title":"Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus","volume":"1108","author":"Kiss","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511x-11-92","article-title":"Modulation of paraoxonases during infectious diseases and its potential impact on atherosclerosis","volume":"11","author":"Farid","year":"2012","journal-title":"Lipids Health Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.136762","article-title":"Lupus atherosclerosis prevention study (LAPS)","volume":"70","author":"Petri","year":"2011","journal-title":"Ann Rheumatic Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/art.42722","article-title":"Atherosclerosis progression in the APPLE trial can be predicted in young people with juvenile-onset systemic lupus erythematosus using a novel lipid metabolomic signature","volume":"76","author":"Peng","year":"2024","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-025-01267-0","article-title":"Immunometabolism in systemic lupus erythematosus","volume":"21","author":"Pati\u00f1o-Martinez","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.147","article-title":"Oxidative stress in the pathology and treatment of systemic lupus erythematosus","volume":"9","author":"Perl","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12090226","article-title":"Mitochondrial dysfunction in systemic lupus erythematosus: insights and therapeutic potential","volume":"12","author":"Poznyak","year":"2024","journal-title":"Dis (Basel Switzerland)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.118.313591","article-title":"Immunity and inflammation in atherosclerosis","volume":"124","author":"Wolf","year":"2019","journal-title":"Circ Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00584-1","article-title":"How the immune system shapes atherosclerosis: roles of innate and adaptive immunity","volume":"22","author":"Roy","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cells12192359","article-title":"Innate immune pathways in atherosclerosis-from signaling to long-term epigenetic reprogramming","volume":"12","author":"Aronova","year":"2023","journal-title":"Cells"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2001","article-title":"The immune system in atherosclerosis","volume":"12","author":"Hansson","year":"2011","journal-title":"Nat Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.115.306256","article-title":"Macrophage phenotype and function in different stages of atherosclerosis","volume":"118","author":"Tabas","year":"2016","journal-title":"Circ Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1172\/jci29950","article-title":"Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata","volume":"117","author":"Swirski","year":"2007","journal-title":"J Clin Invest"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.117.312509","article-title":"Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis","volume":"122","author":"Cochain","year":"2018","journal-title":"Circ Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2011.07.001","article-title":"How dendritic cells shape atherosclerosis","volume":"32","author":"Koltsova","year":"2011","journal-title":"Trends Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.111.257535","article-title":"Multiple roles for neutrophils in atherosclerosis","volume":"110","author":"Soehnlein","year":"2012","journal-title":"Circ Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.0000163262.83456.6d","article-title":"Myeloperoxidase and cardiovascular disease","volume":"25","author":"Nicholls","year":"2005","journal-title":"Arteriosclerosis Thrombosis Vasc Biol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arteriosclerosis Thrombosis Vasc Biol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/jci119465","article-title":"IFN-gamma potentiates atherosclerosis in ApoE knock-out mice","volume":"99","author":"Gupta","year":"1997","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nm1343","article-title":"Natural regulatory T cells control the development of atherosclerosis in mice","volume":"12","author":"Ait-Oufella","year":"2006","journal-title":"Nat Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1097\/mol.0b013e32833dc7f9","article-title":"Interleukin-17: friend or foe in atherosclerosis","volume":"21","author":"Tedgui","year":"2010","journal-title":"Curr Opin Lipidology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00395-016-0589-7","article-title":"Protective and pathogenic roles of CD8(+) T cells in atherosclerosis","volume":"111","author":"Cochain","year":"2016","journal-title":"Basic Res Cardiol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029371","article-title":"Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation","volume":"7","author":"Kyaw","year":"2012","journal-title":"PloS One"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902199","article-title":"A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs","volume":"184","author":"Denny","year":"2010","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-42894-5_11","article-title":"Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus","volume":"66","author":"Smith","year":"2014","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/art.23035","article-title":"Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus","volume":"56","author":"Lee","year":"2007","journal-title":"Arthritis Rheumatism"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-089086","article-title":"Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis","volume":"110","author":"Denny","year":"2007","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.581385","article-title":"IFN-I mediates dysfunction of endothelial progenitor cells in atherosclerosis of systemic lupus erythematosus","volume":"11","author":"Ding","year":"2020","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0909927107","article-title":"Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis","volume":"107","author":"Hakkim","year":"2010","journal-title":"PNAS"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713581","article-title":"The role of neutrophil extracellular traps (NETs) in the pathogenesis of systemic lupus erythematosus and antiphospholipid syndrome","volume":"24","author":"Reshetnyak","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012604","article-title":"Non-traditional pro-inflammatory and pro-atherosclerotic risk factors related to systemic lupus erythematosus","volume":"23","author":"Richter","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051061","article-title":"HDL in immune-inflammatory responses: implications beyond cardiovascular diseases","volume":"10","author":"Bonacina","year":"2021","journal-title":"Cells"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.33963\/v.kp.98520","article-title":"Neutrophil extracellular traps (NETs) in cardiovascular diseases: from molecular mechanisms to therapeutic interventions","volume":"81","author":"Natorska","year":"2023","journal-title":"Kardiologia Polska"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/art.21976","article-title":"Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"54","author":"McMahon","year":"2006","journal-title":"Arthritis Rheumatism"},{"key":"B80","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-024-01954-6","article-title":"Metabolic regulation of the immune system in health and diseases: mechanisms and interventions","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110285","article-title":"USP18 induction regulates immunometabolism to attenuate M1 signal-polarized macrophages and enhance IL-4-polarized macrophages in systemic lupus erythematosus","volume":"265","author":"Lai","year":"2024","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/life14060716","article-title":"Crosstalk between inflammation and atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus: is there a common basis","volume":"14","author":"Sircana","year":"2024","journal-title":"Life (Basel Switzerland)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1492726","article-title":"Systemic lupus erythematosus and atherosclerosis: immune pathways and the uncharted territory of gut microbiota and metabolism","volume":"16","author":"Pan","year":"2025","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104802","article-title":"Impaired metabolism predicts coronary artery calcification in women with systemic lupus erythematosus","volume":"96","author":"Urbain","year":"2023","journal-title":"EBioMedicine"},{"key":"B85","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11883-025-01294-y","article-title":"The atherosclerotic plaque microenvironment as a therapeutic target","volume":"27","author":"Pandit","year":"2025","journal-title":"Curr Atheroscl Rep"},{"key":"B86","doi-asserted-by":"publisher","first-page":"8255","DOI":"10.1038\/s41467-025-63202-x","article-title":"Integrated single-cell atlas of human atherosclerotic plaques","volume":"16","author":"Traeuble","year":"2025","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.120.316770","article-title":"Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics","volume":"127","author":"Depuydt","year":"2020","journal-title":"Circ Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/joim.20080","article-title":"Clonal hematopoiesis of indeterminate potential and the risk of autoimmune diseases","volume":"297","author":"Wu","year":"2025","journal-title":"J Internal Med"},{"key":"B90","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/art.30165","article-title":"Interferon-\u03b1 priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-\u03b1 and atherosclerosis in lupus","volume":"63","author":"Li","year":"2011","journal-title":"Arthritis Rheumatism"},{"key":"B91","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.numecd.2017.09.001","article-title":"Disease trends over time and CD4(+)CCR5(+) T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus","volume":"28","author":"Baragetti","year":"2018","journal-title":"Nutrition Metabolism Cardiovasc Diseases: NMCD"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0590-4","article-title":"Single-cell immune landscape of human atherosclerotic plaques","volume":"25","author":"Fernandez","year":"2019","journal-title":"Nat Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J Leukocyte Biol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining 'T cell exhaustion'","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct effector B cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheumatic Dis"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.113.302680","article-title":"Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on \u03b22GPI-specific T cell response","volume":"34","author":"Conti","year":"2014","journal-title":"Arteriosclerosis Thrombosis Vasc Biol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.619690","article-title":"Endothelial cells in emerging viral infections","volume":"8","author":"Fosse","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s42358-019-0055-y","article-title":"Risk factors for cytomegalovirus disease in systemic lupus erythematosus (SLE): a systematic review","volume":"59","author":"Choo","year":"2019","journal-title":"Adv Rheumatol (London England)"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-052814-023338","article-title":"Importance of nucleic acid recognition in inflammation and autoimmunity","volume":"67","author":"Barrat","year":"2016","journal-title":"Annu Rev Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00633-9","article-title":"The type I interferonopathies: 10 years on","volume":"22","author":"Crow","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1578202","article-title":"Metabolic reprogramming in viral infections: the interplay of glucose metabolism and immune responses","volume":"16","author":"Darweesh","year":"2025","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf1970","article-title":"Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus","volume":"376","author":"Perez","year":"2022","journal-title":"Sci (New York NY)"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0113-3","article-title":"Regulation of macrophage immunometabolism in atherosclerosis","volume":"19","author":"Koelwyn","year":"2018","journal-title":"Nat Immunol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cell.2017.12.013","article-title":"Western diet triggers NLRP3-dependent innate immune reprogramming","volume":"172","author":"Christ","year":"2018","journal-title":"Cell"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103760","article-title":"Immunomodulation for accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus","volume":"24","author":"Bartoloni","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B107","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"B108","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheumatic Dis"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2025-0390.o033","article-title":"Atherosclerotic plaque progression and incident cardiovascular events in a 10-year prospective study of patients with systemic lupus erythematosus: the impact of persistent cardiovascular risk factor target attainment and sustained DORIS remission","volume":"77","author":"Papazoglou","year":"2025","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead184","article-title":"The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus","volume":"63","author":"Papazoglou","year":"2024","journal-title":"Rheumatol (Oxford England)"},{"key":"B111","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/rheumatology\/kead329","article-title":"Accelerated atherosclerosis in systemic lupus erythematosus: don't forget the devil we know","volume":"63","author":"van Leuven","year":"2024","journal-title":"Rheumatol (Oxford England)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(24)00131-0","article-title":"Systemic lupus erythematosus: managing cardiovascular risk factors","volume":"6","author":"Rahman","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(20)30004-7","article-title":"Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"2","author":"Sun","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheumatic Dis"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet (London England)"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheumatism"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae192","article-title":"Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment","volume":"64","author":"Dedemadi","year":"2025","journal-title":"Rheumatol (Oxford England)"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet (London England)"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"R117","DOI":"10.1186\/ar3402","article-title":"Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study","volume":"13","author":"Plazak","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/b978-1-4377-0755-7.00152-4","article-title":"Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort","volume":"60","author":"Schanberg","year":"2009","journal-title":"Arthritis Rheumatism"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.023328","article-title":"Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis","volume":"11","author":"Punch","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1002\/art.39070","article-title":"Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis","volume":"67","author":"Feldman","year":"2015","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0074","article-title":"SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action","volume":"43","author":"Packer","year":"2020","journal-title":"Diabetes Care"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104215","article-title":"Cardiorenal protection of SGLT2 inhibitors-perspectives from metabolic reprogramming","volume":"83","author":"Gao","year":"2022","journal-title":"EBioMedicine"},{"key":"B135","doi-asserted-by":"publisher","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041670","article-title":"Anti-inflammatory effects of SGLT2 inhibitors: focus on macrophages","volume":"26","author":"Rykova","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/art.43037","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors for the primary prevention of cardiovascular, renal events, and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: a population-based target trial emulation","volume":"77","author":"Ma","year":"2025","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.16578","article-title":"Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus","volume":"7","author":"Yen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae547","article-title":"A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients","volume":"64","author":"Carlucci","year":"2025","journal-title":"Rheumatol (Oxford England)"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/art.43403","article-title":"Glucagon-like peptide-1 receptor agonist use and the risk of adverse cardiac and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis","volume":"78","author":"Jorge","year":"2026","journal-title":"Arthritis Rheumatol (Hoboken NJ)"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1951981","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1841513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:11:20Z","timestamp":1786011080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1841513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":141,"alternative-id":["10.3389\/fimmu.2026.1841513"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1841513","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1841513"}}